May 17, 2020

Philips Healthcare Mexico: Delivering the continuum of care from hospital to home

Philips
Mexico
Company profile
Health Tech
Admin
2 min
Operating room
In September 2014, Philips announced that it will divide the company in two parts: The first focused on lighting solutions and the second on health tech...

In September 2014, Philips announced that it will divide the company in two parts: The first focused on lighting solutions and the second on health technology. This move will ensure that both divisions can attract the focus they need to remain key players in their respective marketplaces.

For Philips Mexico, it means that actions will focus more and more on providing solutions for healthy living. Where previously the company’s focus was on manufacturing and selling products, in the future Philips will partner long term with key clients in the private and public sectors.

Click here to read the latest edition of Healthcare Global magazine! 

Focus on health tech: Providing care from the hospital to the home

Being a leading supplier of healthcare technology for both private and public hospitals, Philips has always offered the best equipment available for diagnostic imaging and monitoring. Recent additions to this catalogue include the only digital MRI solution currently available in the market, a digital PET-CT solution capable of diagnosing cancer faster and more accurately with half the radiation and a spectral CT scanner, which provides diagnostic precision levels as never seen before.

RELATED TOPIC: CHUM: Montreal’s international health centre

However, Philips Healthcare’s operations now encompass a spectrum not limited to supplying equipment for hospitals alone.

“If we truly want to improve healthcare for Mexicans, we need to look at the full continuum of care,” said Mark Stoffels, and added “This means that we should work to make sure a patient does not have to go to the hospital in the first place. And if they have to, we should try to make their stay as short as possible so that they can soon return to the comfort of their own homes. Our strategy is ... Click here to read the rest of the article on Healthcare Global!

Let's connect!   

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

AI
medication
personalisedmedicine
chronicdisease
3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article